West Pharmaceutical Services Newsroom

Jefferies Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Maintains Target Price $393

Futu NewsNov 20 21:33

Jefferies Sticks to Their Buy Rating for West Pharmaceutical Services (WST)

TipRanksNov 20 21:01

BofA Securities Maintains West Pharmaceutical Services(WST.US) With Buy Rating

Futu NewsOct 25 22:31

Jefferies Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Raises Target Price to $393

Futu NewsOct 25 21:36

Stephens Adjusts Price Target on West Pharmaceutical Services to $380 From $340

MT NewswiresOct 25 21:17

Jefferies Keeps Their Buy Rating on West Pharmaceutical Services (WST)

TipRanksOct 25 20:37

DBS Maintains West Pharmaceutical Services(WST.US) With Buy Rating

Futu NewsOct 15 17:34

DBS Maintains West Pharmaceutical Services(WST.US) With Buy Rating

Futu NewsSep 26 15:32

Analysts Offer Insights on Healthcare Companies: West Pharmaceutical Services (WST) and HCA Healthcare (HCA)

TipRanksSep 26 15:02

Jefferies Adjusts Price Target on West Pharmaceutical Services to $345 From $426

MT NewswiresJul 29 21:10

Jefferies Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Cuts Target Price to $345

Futu NewsJul 29 20:33

Stephens Adjusts Price Target on West Pharmaceutical Services to $340 From $400

MT NewswiresJul 26 21:16

Hold Rating on West Pharmaceutical Services Amid Forecast Challenges and Demand Slowdown

TipRanksJul 26 15:11

Stephens Adjusts Price Target on West Pharmaceutical Services to $400 From $420

MT NewswiresJul 16 21:10

Jefferies Adjusts Price Target on West Pharmaceutical Services to $426 From $423

MT NewswiresApr 26 23:16

West Pharmaceutical Services: Strong Q1 Performance and Upbeat FY24 Outlook Bolster Buy Rating

TipRanksApr 26 17:15

Buy Rating Affirmed for West Pharmaceutical Services on Robust Market Position and Growth Prospects

TipRanksFeb 22 15:05

West Pharmaceutical Servs Analyst Ratings

BenzingaFeb 17 02:34

Deutsche Bank Raises West Pharmaceutical Services Price Target to $355 From $350, Maintains Hold Rating

MT NewswiresFeb 16 23:33

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bio-Rad Laboratories (BIO), Ultragenyx Pharmaceutical (RARE) and West Pharmaceutical Services (WST)

TipRanksFeb 16 21:40